Trial Profile
PREVENTION OF THE PROGRESSION OF VERY EARLY SYMPTOMS INTO ANKYLOSING SPONDYLITIS:A PLACEBO CONTROLLED TRIAL WITH ETANERCEPT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2020
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms PREVAS
- Sponsors Wyeth
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 06 Jun 2020 Status changed from recruiting to completed as per the results presented at the 21st Annual Congress of the European League Against Rheumatism.
- 31 Aug 2009 New trial record